Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550348 | 0.89 | ALDH1A1 (0.51) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL15602928 | 0.88 | ALDH1A1 (0.52) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL2548974 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL12282151 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL2551664 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL2549846 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL12282460 | 0.74 | MEN1 (0.43) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL14229560 | 0.74 | ACHE (0.48) | ALDH1A1KDM4ETSHRPOLBKMT2A | |
| SCHEMBL14229564 | 0.73 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRPOLBTDP1 | |
| SCHEMBL8160809 | 0.72 | APLNR (0.54) | ALDH1A1KDM4EAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| EP-2552923-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Janssen R&D Ireland (IE) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | ALDH1A1 2328/4885KDM4E 911/4885TSHR 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.